Novo Nordisk Raises Guidance on Surging Demand
Wall Street Journal
Novo Nordisk now expects 2023 sales growth of 27%-33% and operating profit growth of 31%-37%, as demand for its Ozempic diabetes drug and Wegovy obesity treatment continued to rise.
Wall Street Journal
Novo Nordisk now expects 2023 sales growth of 27%-33% and operating profit growth of 31%-37%, as demand for its Ozempic diabetes drug and Wegovy obesity treatment continued to rise.